IRRAS Partners with Lovell Government Services to Expand Distribution Capabilities to U.S. Military and Veterans


IRRAS ‘IRRAflow and Hummingbird product lines for neurocritical care will be available through government contract vehicles established by Lovell

Stockholm, 23 December 2021 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that it has entered into a non-exclusive distribution agreement with Lovell Government Services, a small business owned by Disabled Veterans (“SDVOSB”), to serve as the Company’s supplier for product orders and contract awards. United States government facilities. This partnership will allow IRRAS to accelerate the launch of its IRRAto flow and Hummingbird ICP using Lovell’s position as a contract supplier to Veterans Affairs (VA) hospitals and others United States government and military medical facilities.

“The IRRAS sales team is delighted to partner with Lovell’s government services team due to their extensive experience and established contracts with Virginia and military medical facilities will provide strategic advice and benefits as we grow within this important client group, ”said Will martin, Chairman and CEO of IRRAS. “Our IRRAS team is dedicated to bringing innovative and life-saving technology to all patients, but it is especially important that this partnership allows us to have a positive impact on the lives of more patients who have volunteered. to serve their country. “

Lovell, a small business owned by disabled veterans, is ranked by Inc. 5000 as the fastest growing private company in 2021. It partners with medical and pharmaceutical companies seeking to serve veteran patient populations and military and to compete for government contracts. Through this partnership, federal, state and local government agencies will be able to place orders for ARIFto flow or Hummingbird ICP through appropriate contract vehicles, such as the Defense Logistics Agency ECAT system, Federal Supply Schedule (FSS), Distribution and Pricing Agreement (DAPA) and GSA Advantage for direct purchase. Partnering with an SDVOSB also benefits government agencies by helping them meet their SDVOSB procurement goals and requirements.

“IRRAS has developed innovative devices dedicated to the treatment of intracranial hemorrhages and head trauma, which unfortunately disproportionately affect the communities we serve. IRRAto flow and Hummingbird aircraft will save and improve the lives of thousands of veterans, active-duty service members and their dependents. We are honored that IRRAS is partnering with us ”, declares Chris Lovell, Major, USMC (retired) and CEO of Lovell Government Services.

About Lovell Government Services

Lovell Government Services was created by Chris Lovell, Retired Major USMC, in 2013. Lovell’s mission is to serve the hospital system of the Veterans Administration, the we Military medical networks, other federal health systems and the communities they support. Lovell partners with medical and pharmaceutical vendors to accelerate and distribute the latest lifesaving technologies to the federal government. Learn more at


IRRAS is a global healthcare company focused on providing innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops and markets neurocritical care products that transform patient outcomes and reduce the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its complete and innovative IRRAto flow and Hummingbird ICP Monitoring to hospitals around the world through its direct sales organization in United States and some European countries as well as an international network of distribution partners.

IRRAS is headquartered in Stockholm, Sweden, with head offices at Munich, Germany, and San diego, california, UNITED STATES. For more information, please visit

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information please contact:

Sten gustafssonDirector, Investor Relations
+46 102 11 5172

The information has been made public, through the contact above, on 23 December 2021, at 8:30 a.m. (CET).,c3477772

(c) Decision 2021. All rights reserved., source Press Releases – English


Leave A Reply